Comparative analysis reports similar survival outcomes in early-stage DLBCL for Black and White patients, suggesting broader implications for treatment access.
Black patients have been reported to have worse survival for DLBCL, considering all stages collectively. The remarkable finding of our study was that despite disparities in socioclinical determinants, no overall survival difference was observed between Black and White patients with early-stage DLBCL. We suggest that the similar survival in early-stage DLBCL for Black and White patients is primarily overcome by the favorable remission rate of early-stage DLBCL and accessibility to conventional chemoimmunotherapy. We also imply that the survival disparity between Black and White patients in DLBCL is more likely to be the impact of socioclinical determinants on advanced stage III/IV DLBCL.
No takes yet. Share an insight, caveat, or question.
Herrán et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: